RedKnight in numbers


Proposals Submitted


Average application score


Company awards


of funding secured


Seal of excellence awards


Success rate

Since launching in September 2015, RedKnight has secured over £10 million of funding to support our clients’ innovative products, processes and services, of which over £3 million has been awarded to Welsh companies. Helping Wales based companies grow is RedKnight's core mission, but that does not mean we don't work further afield. Since day one, we have set a global reach that has allowed us to work with over 100 companies around the world.

Since launching in September 2015, RedKnight has secured over £9.9 million of funding to support innovative Welsh companies. Helping Wales grow is RedKnight's core mission, but we have also set a global reach that has allowed us to work with over 100companies around the world.

Here is a selection of our most recent successes. Hover over a project to learn more.



Eureka Eurostars

Free Space Optical Links for 5G networks (FrOLik)

FrOLik aims to deliver a novel Free Space Optical (FSO) communication product for 5G infrastructure deployment. To achieve this, they will leverage a structured laser beam technology with high-performance detector technology and new high-speed component integration techniques. Significantly, the product will address an existing trade-off between bandwidth and range of backhaul with clear advantages: i) Compared to fibre optic links, the system is easily deployable and cost effective and ii) Compared to microwave links the system is easier to upgrade, requires no spectrum licenses, and consumes at least 10% less electricity.


€578, 684

Eureka Eurostars

Multi-Modal Medical Mapper (M4)

M4 aims to deliver a prototype of a portable camera that integrates 3D scanning, visual and (thermal) infrared imaging modalities. The three representational characteristics will be captured and displayed in a single 3D representation. The project is disruptive in the digital medical devices sector; there are no existing devices capable of performing all functions at the same time. Therefore, this device opens entirely new possibilities for prevention, diagnosis, and treatment, in areas including Diabetic Foot Ulcer treatment, medical aesthetics and wound healing.



Eureka Eurostars


Funded through the Eureka Eurostars programme, the REDEEMA project will design and develop an inexpensive manufacturable (III-V semiconductor material based) resonant cavity enhanced photodiode (RCE-PD) infrared (IR) sensing array for monitoring greenhouse gases (GHGs), such as carbon dioxide, methane and nitrous oxide. A paradigm in high sensitivity mid-IR GHG sensing, the REDEEMA sensor will aid existing analytical instrumentation in the intelligent field deployment of the quantitative analysers and/or in the determination of gas sources. It will improve performance and open many new opportunities with environment applications.



Horizon 2020


The RAPID-COVID project aims to clinically validate its innovative multiplex technology in both point of care and high throughput (HTP) settings. This is in response to the need for faster and better detection of multiple respiratory pathogens. Their prototype will simultaneously detect and differentiate SARS-CoV-2 as well as 30 other common respiratory bacteria and viruses. GeneFirst’s assay will allow for accurate, cost-effective, and comprehensive diagnoses during the current outbreak, as well as future routine diagnosis. The strategy provides maximum flexibility for screening and triage, allowing better and faster care and alleviating pressures on healthcare systems.



Innovate UK

eMR Health Passport

Using the company’s flagship proprietary software, eMR, Medi2Data develops highly secure applications that make it simple for GP practices and patients to exchange data. The healthcare software company will use its Innovate UK Smart Grant to further develop its interactive mobile application, ‘eMR Health Passport.’ The application securely holds a copy of the patient’s medical record in an easy-to-navigate format. The eMR passport will reduce the costs that primary care currently faces, simultaneously improving patient outcomes and the relationship between GP and patient.



Innovate UK


With funding from Innovate UK, Metis will create a wearable technology as a digital solution to the void that exists between patients suffering with Chronic Obstructive Pulmonary Disease (COPD) and their doctors. Such ``clinical whitespace`` often causes a dramatic loss of relevant patient data which could be better used to provide more effective COPD management. Thanks to this grant, Bond will be able to further develop the product which will equip medical practitioners with independent, accurate analysis of patient data providing valuable, comprehensive insights and evidence-based care.



Innovate UK


The DeepADMET project aims to develop a Next-Generation Platform for Novel Drug Discovery, using Deep Learning of ``absorbption, distribution, metabolism and excretion-toxicity`` (ADMET properties). Poor ADMET properties are the cause of almost 56% of drug failures in pre-clinical and clinical development, generating upd to $1.4bn losses worldiwide. Thanks to DeepADMET, a new modelling method is now available: by employing modern ‘Artificial Intelligence’ (AI) methods and applying these methods to modelling pre-gathered ADMET data, researchers can now provide more robust and precise ADMET properties.



Eureka Eurostars


Funded through the Eureka Eurostars Actions within the H2020 Programme, MISCA aims to provide Monolitically Integrated detector Solutions for next-generation Comms Applications. Current optical communications infrastructures cannot sustain the increasing bandwith demand, without massively increase power consumption. Thus, MISCA uses intelligent monolithic integration of compound semiconductor materials platforms to deliver high-speed detector solutions with co-optimised RF and optical performance, to deliver increased chip-scale specification and reduce operating power requirements.



Fast Track to Innovation


The BreathSpec project aims to develop a rapid, non-invasive device that can diagnose bacterial or viral infections through ultra-high sensitivity breath analysis. Once developed the BreathSpec device will help reduce the development of anti-bacterial resistance and alleviate the growing problem of antimicrobial resistance (AMR) through improved diagnosis of antibiotic treatment. The device will also reduce the scientific, clinical and financial challenges associated with the development of new antibiotics.



Innovate UK


The CADDNOR project aims to develop a point of care (POC) diagnostics and carbohydrate-based therapeutics, focused on the detection of Norovirus. The developed assay uses glyconanoparticle technology with potential for replacing molecular technologies and immunodiagnostics – a major shift in analytical approach. The use of carbohydrates instead of antibodies as the recognition mechanism has several advantages including their production using industrial scale, cost-effective chemoenzymatic synthesis which addressed the call topic.



Horizon 2020


Funded through the Marie Sklodowska-Curie Actions, TALK aims to guide multi-professional clinical teams learning and improve the quality of patient care and safety. Consisting of 5 partners across 3 countries, TALK will research the benefits of structured debriefing, communication and organisational culture. Using this data, further training materials will be developed and translated to support the wider deployment of the tool, which will be widely disseminated and implemented across and beyond all participating partners.



SME Instrument


Funded by the SME Instrument within the H2020 programme, Thermetrix’s disruptive technology PODIUM uses a combination of thermochromic liquid crystal sheet and high-res cameras, to provide a state-of-the-art diabetic foot monitor that can provide accurate early warning on the formation of Diabetic Foot Ulcers (DFUs). The thermal patterns so picked up by PODIUM will be transmitted to a cloud portal helping patients, family and medical staff to detect and immediately treat conditions before the onset of ulceration. In this way, stress and inflammation can be reduced, tissue damage limited and the foot will return to normal. Critically, up to 80% of DFUs may be avoided.